Asthma

May 15th 2024

The continuation of tezepelumab showed stronger benefits after stopping treatment for 2 years and compared with placebo.

May 9th 2024

This study is the first to preliminarily show that a community pharmacist intervention can produce a positive effect on reducing SABA reliance and improvement of ICS adherence in patients with asthma.

May 8th 2024

SMART uses an ICS and a long-acting beta-2 agonist (LABA) product, giving patients 4 years and older with moderate to severe uncontrolled persistent asthma 1 inhaler for dual symptom relief.

May 5th 2024

With these findings contributing to the understanding of neighborhood-level asthma risks, the authors note next steps can involve identifying and addressing disparities.